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ABSTRACT 
Objective: This study was aimed to develop a simple, rapid, specific and precise liquid chromatography-tandem mass spectrophotometric (LC–
MS/MS) validated method for quantification of Boceprevir and internal standard (ISTD) Boceprevir D6 in human plasma. 
Methods: Plasma samples were pretreated with 100 µl of 0.1N Sodium Hydroxide and are subjected for Liquid-Liquid Extraction (LLE) using 2.5 ml 
of ethyl acetate. Chromatographic separation was achieved on Chromolith RP18e column (100 mmx4.6 mmx5 µm) with Acetonitrile: 20 mM 
Ammonium formate (80:20%v/v) as an isocratic mobile phase with a flow rate of 1.2 ml/min. the LC eluent was split, and approximately 0.1 
ml/min was introduced into Tandem mass spectrometer using turbo Ion Spray interface at 400 °C. Quantitation was performed by transitions of 
m/z 586.2 precursor ion to the m/z 422.2 for Boceprevir and m/z 592.2/574.20 for Boceprevir D6.  
Results: The concentrations of nine working standards showed linearity between 2 to 1000 ng/ml (r2
Conclusion: The assay is suitable for pharmacokinetic study samples as demonstrated by its specificity, precision, accuracy, recovery, and stability 
characteristics. 
 ≥ 0.998). Chromatographic separation was 
achieved within 3 min. The limit of Quantification (LOQ) was found to be 2ng/ml. The intraday and interday precision with quality control samples 
was found to be 0.09 to 3.17%. 
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INTRODUCTION 
Boceprevir, (1R 3-{[(1R,2S,5S)-3-[(2S)-2-[(tertbutyl carbamoyl) amino] -
3,3-dimethylbutanoyl]-6,6-dimethyl-3-azabicyclo [3.1.0] hexan-2-yl] 
formamido}-4-cyclobutyl-2-oxobutanamide, is a protease inhibitor 
used in treatment of hepatitis caused by hepatitis C virus (HCV) 
genotype 1 in combination with peginterferon and ribovirin [1-3]. 
One RP-HPLC Method was developed for the estimation of 
boceprevir from its bulk and dosage forms [4]. LC-MS/MS method 
was reported for characterization of human liver enzymes in the 
biotransformation of boceprevir [5]. Second LC-MS/MS method was 
developed for in vitro study of drug-drug interactions of boceprevir 
with metabolic enzymes and transporters [6]. Only two LC-MS/MS 
methods were reported for simultaneous estimation of boceprevir in 
combination with other drugs from human plasma [7-8]. Literature 
survey reveals, there are no HPLC and LC-MS/MS methods for 
quantitative estimation of boceprevir alone from Human Plasma. 
We, therefore, aimed to develop a simple, rapid, robust, and efficient 
HPLC-MS/MS validated method for the quantification of boceprevir 
from human plasma using boceprevir D6 as internal standard 
employing an economical liquid-liquid extraction technique. 
MATERIALS AND METHODS 
Apparatus and software 
The HPLC system with an autosampler was a Shimadzu LC-20ADvp 
(Shimadzu, Japan) coupled with Applied Biosystem Sciex (MDS 
Sciex, Canada) API 3000 Tandem mass spectrometer. The 
autosampler was SIL-HTC from Shimadzu, Japan. The solvent 
delivery module was LC-20AD from Shimadzu, Japan. The 
chromatographic integration was performed by Analyst software 
(version: 1.4.2; Applied Biosystems).  
Chemicals and reagents 
Boceprevir and Boceprevir D6 (IS) were procured from Unichem 
Laboratories Ltd., Mumbai, India; Formic acid was procured from 
Merck Specialities Pvt. Ltd, Mumbai, India. Water used was collected 
from water purification systems (Milli Q, Milli Pore, USA) installed in 
the laboratory. Methanol and acetonitrile were of HPLC grade and 
were supplied by J. T. Baker, USA. Pooled drug-free expired frozen 
human plasma (K2-EDTA as anticoagulant) was obtained from St. 
Theresa Blood Bank, Hyderabad, was used during validation and 
study sample analysis. The plasma was stored into-70±5o
Standards and working solutions 
C. 
Calibration standard solutions 
Stock solutions of Boceprevir and Boceprevir D6 internal standard (IS) 
were prepared in methanol. Further dilutions were carried out in Formic 
acid in Methanol (0.1%v/v): Water 50:50 v/v. Calibration standards of 
nine concentration levels were prepared freshly by spiking drug-free 
plasma with Boceprevir stock solution to give the concentrations of 2.00, 
4.00, 10.00, 25.0, 50.0, 125, 250, 500, and 1000ng/ml 
Quality control standards 
Lowest quality control standards, Median quality control standards 
and highest quality control standards were prepared by spiking 
drug-free plasma with Boceprevir to give a solution containing 6, 
400and 800ng/ml respectively. They were stored at-20 °c till the 
time analyzed. 
Chromatographic conditions 
Chromatographic separation was performed on a Chromolith RP18e 
(100 mmx4.6 mmx5 µm), analytical column and the mobile phase 
was Acetonitrile: 20 mM Ammonium formate (80:20% v/v) as an 
isocratic mobile phase with a flow rate of 1.2 ml/min. Injection 
volume was 10μl. Total analysis time of single injection was 5.00 
min. Column oven temperature and autosampler temperature was 
set to 40 °C and 5 °C, respectively.  
Mass spectrometric conditions 
The LC eluent was split, and approximately 0.100 ml/min was 
introduced, and Quantitation was achieved with MS/MS detection in 
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positive ion mode for the analytes and IS using a MDS Sciex API-
4000 mass spectrometer (Foster City, CA, USA) equipped with 
Turboion spray™ interface at 400 °C. The ion spray voltage was set 
at 5500 V. The source parameters viz., the nebulizer gas, curtain gas, 
CAD gas were set at 40, 30 and 5 psi, respectively. The compound 
parameters viz. the declustering potential (DP), collision energy 
(CE), entrance potential (EP) and collision cell exit potential (CXP) 
for MT and MT-d6  were similar and are 105, 32, 10, 14 V. For FF and 
FF-d10 the DP, CE, EP and CXP were 100, 36, 10 and 15 V. A Turbo 
ion spray interface (TIS) operated in positive ionization mode was 
used for the detection. Detection of the ions was carried out in the 
multiple-reaction monitoring mode (MRM), by monitoring the 
transition pairs of m/z 586.2 precursor ion to the m/z 422.2 for 
Boceprevir and m/z 592.2/574.20 for Boceprevir-d6
The % mean recoveries were determined by measuring the 
responses of the extracted plasma Quality control samples at HQC, 
MQC and LQC against un-extracted Quality control samples at HQC, 
MQC and LQC. 
. Quadrupoles 
Q1 and Q3 were set on unit resolution. 
Sample preparation method 
To 200 µl of plasma, 50 µl of Boceprevir D6 (5µg/ml) was added and 
vortexed. The sample was pretreated with 100 µl of 0.1N Sodium 
Hydroxide then extracted with 2.5 ml of ethyl acetate followed by 
centrifugation at 2000 rpm/min on a cooling centrifuge for 15 min 
at 4 °c. The 2 ml of supernatant was withdrawn and dried using 
lyophiliser. The residue was reconstituted in 300 μL of the mobile 
phase, and a 4 μL was injected into the column. 
Validation 
Specificity 
A solution containing 2.0ng/ml was injected onto the column under 
optimized chromatographic conditions to show the separation of 
Boceprevir from impurities and plasma. The specificity of the 
method was checked for the interference from plasma. 
Linearity 
Spiked concentrations were plotted against peak area ratios of 
Boceprevir to the internal standard and the best fit line was 
calculated. Wide range calibration was determined by solutions 
containing 2ng/ml to 1000ng/ml. 
Recovery studies 
Precision and accuracy 
Intraday precision and accuracy was determined by analyzing 
quality control standards (6, 400and 800ng/ml) and LLOQ 
Quality control standard (2.00 ng/ml) five times a day randomly, 
interday precision and accuracy was determined from the 
analysis of each quality control standards (6, 400and 800ng/ml) 
and LLOQ Quality Control standards (2.00 ng/ml) once on each 
of five different days. 
Matrix effect 
The matrix effect for the intended method was assessed by using 
chromatographically screened human plasma. Concentrations 
equivalent to LQC and HQC of Boceprevir were prepared with six 
different lots of plasma and are injected. 
Ruggedness 
Ruggedness was determined by analyzing six replicates of MQC in 
two batches using two different columns.  
RESULTS AND DISCUSSION 
The chromatography observed during the course of validation was 
acceptable and representative chromatograms of standard blank, 
HQC, MQC and LQC samples are shown in (fig. 1 to 4). 
The method developed was validated for specificity, accuracy & 
precision, linearity and stability as per USFDA guidance. The results 
of validating parameters are given below. 
Specificity 
Six different lots of plasma were analyzed to ensure that no 
endogenous interferences were present at the retention time of 
Boceprevir and Boceprevir D6. Six LLOQ level samples along 
with plasma blank from the respective plasma lots were 
prepared and analyzed. (Table-1) shows results of specificity. In 
all plasma blanks, the response at the retention time of 
Boceprevir was less than 20% of LLOQ response and at the 
retention time of IS, the response was less than 5% of mean IS 
response in LLOQ. 
 
  
Fig. 1: Representative blank chromatograms of boceprevir and IS in blank plasma 
 
Table 1: Showing results of specificity for Boceprevir and Boceprevir D6 (ISTD) 









LLOQ % Interference 
Area RT Area RT 
01 41 2169 2.652 1.89 68 470648 2.624 0.01 
02 4 2314 2.651 0.17 17 492693 2.615 0.00 
03 8 1691 2.652 0.47 6 413426 2.635 0.00 
04 8 2016 2.650 0.40 9 478343 2.623 0.00 
05 10 2430 2.653 0.41 9 519770 2.633 0.00 
06 6 1751 2.652 0.34 65 482317 2.627 0.01 
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Fig. 2: Representative HQC-chromatograms of Boceprevir in Plasma with internal standard 
 
  
Fig. 3: Representative MQC-chromatograms of boceprevir and its internal standard 
 
  
Fig. 4: Representative chromatograms of boceprevir and its internal standard at LQC Level 
 
Linearity 
The calibration curve (peak area ratio Vs Concentration) was linear 
over working a range of 2ng/ml to 1000ng/ml with ten point 
calibration used for quantification by linear regression, shown in 
(fig. 5).  
The regression equation for the analysis was Y=0.710-2.318 with a 
coefficient of correction (r2
The % mean recovery for Boceprevir in LQC, MQC and HQC was 
66%, 74.7% and 62.8% respectively (table 2). 
Intraday and interday precision 
The intraday and interday precision of the method was found to be 
0.09 to 3.17% for the quality control samples. This is within the 
acceptance limits of precision is 15%. The limit of Quantification was 
found to be 2ng/ml. at such concentration, the interday and intraday 
precision were found to be 7.54% and 3.52% respectively. Which 
are within the acceptance limits of precision is 20%. (table 3) 
Matrix effect 
) = 0.999. 
Recovery 
The % CV for HQC and LQC samples was observed 1.15% and 4.36% 
respectively (Table 4), which are within 15% as per the acceptance 
criteria. 
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Fig. 5: Spiked concentrations (2ng/ml to1000ng/ml) were plotted against peak area ratio Vs Concentration with nine point calibration 
used for quantification by linear regression 
 
Table 2: Showing % mean recovery of boceprevir for LQC, MQC and HQC 
Replicate 
number 
Extraction recovery studies of boceprevir (analyte-1) 













1 779111 1117607 54310 68298 5935 8185 
2 736269 1127551 52789 68719 5220 8918 
3 721212 1245455 51784 70905 5060 8560 
4 764700 1223297 52137 68785 5420 8409 
5 770962 1232020 50933 69041 6541 9082 
6 743630 1239998 51334 73870 6683 9686 
Mean 752647.3 1197654.5 52214.5 69936.3 5809.8 8806.7 
SD 22444.43 58717.10 1210.79 2130.98 689.18 541.64 
% CV 2.98 4.90 2.32 3.05 11.86 6.15 
% Mean 
recovery 
62.8 74.7 66.0 
% Overall Recovery 68.70 
% Overall CV 7.71 
 
Table 3: Summery of intra-and inter-batch precision and accuracy study 
QC Boceprevir (ng/ml) 
Intra-batch LLOQ QC(2) LQC (6) MQC (400) HQC (800) 
Mean 2.07 6.35 386 820 
SD 0.0703 0.201 4.20 13.2 
%CV 3.52 3.17 1.09 1.61 
% Bias 0.00 5.83 -3.50 2.50 
N 6 6 6 6 
Inter-batch LLOQ QC(2) LQC (6) MQC (400) HQC (800) 
Mean 2.01 5.95 404 767 
SD 0.156 0.109 5.18 7.59 
%CV 7.54 1.83 1.28 0.99 
% Bias 3.50 -0.83 1.00 -4.13 
N 6 6 6 6 
 
Table 4: showing results of matrix effect obtained by preparing LQC and HQC with six different lots of plasma 
QC ID LQC HQC 
Actual conc. (ng/ml) 6 800 
1 5885 769161 
2 5523 771264 
3 5290 751619 
4 5520 766100 
5 5941 766962 
6 5683 751610 
Mean 5640.333 762786 
±SD 246.1964 8837.913 
% CV 4.364926 1.158636 
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Table 5: Showing the results of ruggedness 
QC ID MQC MQC 
S. No. Column-1 Column-2 
1 64310 65298 
2 62789 66719 
3 61784 67905 
4 62137 68485 
5 60933 67041 
6 61334 63870 
Mean 62214.5 66553 
±SD 1210.787 1708.786 
% CV 1.94615 2.567556 
 
Ruggedness 
The ruggedness for two batches of MQC (n=6) was obtained using 
two different columns. The % CV for batch-1 MQC and batch-2 MQC 
were found 1.9 and 2.5 respectively (table 5), which is within 
acceptance limits of 15% 
CONCLUSION 
The analytical method developed and validated for the quantitative 
determination of boceprevir from plasma was simple, rapid, specific, 
sensitive, accurate and precise. Hence, the method is quite suitable 
to detect the drug from plasma samples of human volunteers and for 
pharmacokinetic studies. 
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